Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Malignant Neoplasm × trametinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Melanoma 34 Carcinoma, Non-Small-Cell Lung 9 Thyroid Neoplasms 8 Thyroid Carcinoma, Anaplastic 8 Neoplasms 8 Colorectal Neoplasms 8 Neoplasm Metastasis 6 Multiple Myeloma 5 Glioma 5 Pancreatic Neoplasms 4 Brain Neoplasms 4 Recurrence 3 Neurofibromatosis 1 3 Lung Neoplasms 3 Hematologic Neoplasms 3 Ameloblastoma 3 Thyroid Cancer, Papillary 2 Skin Neoplasms 2 Rectal Neoplasms 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neurofibroma, Plexiform 2 Myelodysplastic Syndromes 2 Meningioma 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myelomonocytic, Chronic 2 Leukemia, Myeloid, Acute 2 Colonic Neoplasms 2 Breast Neoplasms 2 Astrocytoma 2

Interventions

trametinib 1 dabrafenib 1 Surgical Procedures, Operative 1 Pharmaceutical Preparations 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡